Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 16/20 | 0.73 |
| ▸ | ACHE | P22303 | 5/20 | 0.69 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.68 |
| ▸ | HTR1A | P08908 | 1/20 | 0.59 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.59 |
| ▸ | HTR2A | P28223 | 1/20 | 0.59 |
| ▸ | HTR2C | P28335 | 1/20 | 0.59 |
| ▸ | DRD3 | P35462 | 1/20 | 0.59 |
| ▸ | HTR2B | P41595 | 1/20 | 0.59 |
| ▸ | HTR6 | P50406 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30300504 | 1.00 | BCHE (0.73) | BCHEACHENOX1HTR1AADRB3 | |
| Pyrrole SCHEMBL8426380 | 0.89 | BCHE (0.59) | BCHEACHENOX1 | |
| Diethanolamine SCHEMBL9727343 | 0.85 | BCHE (0.54) | BCHEACHENOX1 | |
| SCHEMBL8739172 | 0.84 | BCHE (0.76) | BCHEACHENOX1 | |
| SCHEMBL27597035 | 0.82 | BCHE (0.51) | BCHEACHENOX1HTR1AADRB3 | |
| SCHEMBL343497 | 0.82 | BCHE (1.00) | BCHEACHENOX1 | |
| SCHEMBL7249195 | 0.81 | ALDH1A1 (0.48) | BCHEACHENOX1 | |
| SCHEMBL522271 | 0.81 | BCHE (0.70) | BCHEACHENOX1 | |
| SCHEMBL341905 | 0.81 | NOX1 (1.00) | BCHEACHENOX1 | |
| SCHEMBL4778133 | 0.81 | BCHE (0.70) | BCHEACHENOX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5861394-A | COMPOUNDS AS ANTIISCHEMIC AGENTS, TREATMENT OF STROKES, ANTIHEMORRHEGENIC AGENTS, ANTIDEPRESSANTS OR TREATMENT OF SICKKLE CELL ANEMIA | BAYER AKTIENGESELLSCHAFT (DE) | 1999-01-19 | — | — | US | claimed |
| CN-1867566-B | Aminopyranones and their use as ATM inhibitors | KUDOS PHARM LTD | 2010-06-16 | — | — | CN | disclosed |
| EP-1535890-B1 | METHOD FOR PRODUCING P-DICHLOROBENZENE | KUREHA CORP (JP) | 2009-05-27 | — | — | EP | disclosed |
| CN-100358891-C | Pyranones useful as ATM inhibitors | KUDOS PHARM LTD (GB) | 2008-01-02 | — | — | CN | disclosed |
| CN-1301945-C | Method for producing p-dichlorobenzene | KUREHA CHEMICAL IND CO LTD (JP) | 2007-02-28 | — | — | CN | disclosed |
| US-20070043024-A1 | Azacyclic compounds as inhibitors of sensory neurone specific channels | IONIX PHARMACEUTICALS LIMITED (GB) | 2007-02-22 | — | — | US | disclosed |
| CN-1867566-A | Aminopyranones and their use as ATM inhibitors | KUDOS PHARM LTD (GB) | 2006-11-22 | — | — | CN | disclosed |
| EP-1535890-A4 | METHOD FOR PRODUCING P-DICHLOROBENZENE | KUREHA CORP (JP) | 2006-08-09 | — | — | EP | disclosed |
| EP-1660454-A1 | AZACYCLIC COMPOUNDS AS INHIBITORS OF SENSORY NEURONE SPECIFIC CHANNELS | Vernalis (R&D) Limited (GB) | 2006-05-31 | — | — | EP | disclosed |
| CN-1678550-A | Method for producing p-dichlorobenzene | KUREHA CHEMICAL IND CO LTD (JP) | 2005-10-05 | — | — | CN | disclosed |
| CN-1639154-A | Pyranones useful as ATM inhibitors | KUDOS PHARM LTD (GB) | 2005-07-13 | — | — | CN | disclosed |
| WO-2005005392-A1 | AZACYCLIC COMPOUNDS AS INHIBITORS OF SENSORY NEURONE SPECIFIC CHANNELS | IONIX PHARMACEUTICALS LIMITED (GB) | 2005-01-20 | — | — | WO | disclosed |
| US-6825383-B1 | HALOGENATION USING METAL CHLORIDE IN PRESENCE OF HYPERVALENT IODINE CATALYST; QUALITY INSECTICIDES, FUNGICIDES, HERBICIDES, DYES, AND PHARMACEUTICALS | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2004-11-30 | — | — | US | disclosed |
| WO-2004022512-A1 | METHOD FOR PRODUCING p-DICHLOROBENZENE | KUREHA CHEMICAL INDUSTRY COMPANY, LIMITED (JP) | 2004-03-18 | — | — | WO | disclosed |
| US-5142045-A | Xanthene, acridine, and thioxanthene moieties pendant from polymer background | AISIN SEIKI KABUSHIKI KAISHA (JP) | 1992-08-25 | — | — | US | disclosed |
| US-4192883-A | ANTITUSSIVES | PIERRE FABRE, S.A. (FR) | 1980-03-11 | — | — | US | disclosed |
| US-4192883-A | ANTITUSSIVES | PIERRE FABRE, S.A. (FR) | 1980-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043024-A1 | Azacyclic compounds as inhibitors of sensory neurone specific channels | SCN1B, SCN1A, SCN10A | BCHE 1165/4885ACHE 186/4885NOX1 1703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.